(Sharecast News) - German science and technology giant Merck announced on Monday that it is to acquire US biopharmaceutical outfit SpringWorks Therapeutics as it attempts to ramp up growth in the healthcare sector.
Merck is paying $47 per share for SpringWorks, representing an equity value of $3.9bn. While only a slight...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE